Skip to main content
. 2021 Jul 20;13:17588359211029826. doi: 10.1177/17588359211029826

Figure 2.

Figure 2.

Currently ongoing clinical studies on immune checkpoint inhibitors (ICIs) developed by multinational corporations (MNCs) and by domestic companies for the treatment of lung cancer in Chinese patients. Among the 52 clinical studies on ICIs, 27 studies assessed six MNC-developed ICIs in Chinese patients (red pie slice) and 25 studies evaluated eight domestically developed ICIs (blue pie slice).